{"entity":{"id":"nct06520488","kind":"trial","name":"A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of HRS-4642 in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.","summary":"A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06520488 by Jiangsu HengRui Medicine Co., Ltd., with 118 participants planned, started 2024-08-09 and due to reach its primary completion in 2027-03. Interventions recorded: HRS-4642.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06520488","url":"https://clinicaltrials.gov/study/NCT06520488"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06520488","phase":"1/2","setting":"Phase IB/II Clinical Study of the Safety, Tolerability and Efficacy of HRS-4642 in Combination With Anti-tumor Agents in Subjects With Advanced Solid Tumors","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","enrolled":118,"outcomes":[]},"route":"/trials/nct06520488/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}